Rocket Pharmaceuticals (RCKT) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Rocket Pharmaceuticals is expected to report Q3 2026 results before the market opens on November 5. Analysts anticipate a loss of $0.39 per share and revenue of approximately $0.20 million; the earnings call is scheduled for November 6.
• The company’s shares opened at $2.58, near their 52-week low of $2.16, with a market capitalization of about $283 million. Rocket reported better-than-expected prior-quarter earnings, but analysts forecast losses for the current and next fiscal years.
• Analyst sentiment is mixed, with the stock carrying a consensus “Hold” rating and an average price target of $7.77. Recent insider sales totaled 125,977 shares, though the transactions were made to cover tax obligations tied to vested equity awards.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Rocket Pharmaceuticals to post earnings of ($0.39) per share and revenue of $0.20 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last issued its earnings results on Monday, August 10th. The biotechnology company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.22. During the same period last year, the business posted ($0.62) EPS. On average, analysts expect Rocket Pharmaceuticals to post ($1.36) EPS for the current fiscal year and ($1.44) EPS for the next fiscal year.

Rocket Pharmaceuticals Stock Performance

Shares of Rocket Pharmaceuticals stock opened at $2.58 on Thursday. The company has a quick ratio of 9.24, a current ratio of 9.24 and a debt-to-equity ratio of 0.05. Rocket Pharmaceuticals has a 52 week low of $2.16 and a 52 week high of $5.45. The firm's 50 day moving average is $3.01 and its two-hundred day moving average is $3.47. The firm has a market capitalization of $283.23 million, a P/E ratio of -15.18 and a beta of 0.50.

Insider Buying and Selling at Rocket Pharmaceuticals

In other news, COO Christopher Stevens sold 36,658 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $3.50, for a total transaction of $128,303.00. Following the completion of the transaction, the chief operating officer directly owned 505,784 shares of the company's stock, valued at $1,770,244. This trade represents a 6.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Martin Wilson sold 75,364 shares of the company's stock in a transaction on Friday, September 11th. The shares were sold at an average price of $3.40, for a total value of $256,237.60. Following the completion of the sale, the general counsel owned 598,489 shares in the company, valued at $2,034,862.60. This represents a 11.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 125,977 shares of company stock valued at $432,273 in the last ninety days. Corporate insiders own 21.30% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on RCKT. Jefferies Financial Group restated a "hold" rating and issued a $2.95 target price on shares of Rocket Pharmaceuticals in a report on Wednesday, October 7th. Weiss Ratings cut shares of Rocket Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 11th. Wedbush reissued an "outperform" rating on shares of Rocket Pharmaceuticals in a research report on Wednesday, October 7th. The Goldman Sachs Group upgraded Rocket Pharmaceuticals from a "sell" rating to a "neutral" rating and lifted their target price for the stock from $3.00 to $4.00 in a research report on Thursday, October 8th. Finally, Chardan Capital reiterated a "buy" rating and issued a $11.00 price target on shares of Rocket Pharmaceuticals in a research report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $7.77.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare and devastating diseases. The company uses lentiviral and adeno-associated virus (AAV) technologies to address genetic disorders with significant unmet medical needs, including hematologic, metabolic, and cardiovascular conditions.

Rocket's pipeline has included RP-L102 for Fanconi anemia, a rare inherited bone-marrow-failure disorder; RP-L201 for leukocyte adhesion deficiency-I, an immune disorder; and gene therapy programs targeting Danon disease and arrhythmogenic cardiomyopathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.